ストックスクリーナーアプリを入手
12.79
0.95%
0.12
アフターアワーズ：
12.79
前日終値:
$12.67
開ける：
$12.95
24時間の取引高:
501.71K
Relative Volume:
0.46
時価総額：
$1.02B
収益：
$175.11M
当期純損益:
$-221.25M
株価収益率:
-4.1914
EPS:
-3.0515
ネットキャッシュフロー:
$-167.00M
1週間 パフォーマンス:
+8.30%
1か月 パフォーマンス:
+23.34%
6か月 パフォーマンス:
-4.91%
1年 パフォーマンス:
+168.13%
1日の値動き範囲:
$12.69
$13.03
1週間の範囲:
$11.59
$13.19
52週間の値動き範囲:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.79 | 1.01B | 175.11M | -221.25M | -167.00M | -3.0515 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-12-12 | 開始されました | Raymond James | Strong Buy |
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Responsive Playbooks and the PHAT Inflection - Stock Traders Daily
Aug Highlights: Is Phathom Pharmaceuticals Inc a cyclical or defensive stock2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
[ARS] Phathom Pharmaceuticals, Inc. SEC Filing - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) sets 2026 virtual meeting, director elections and say-on-pay vote - Stock Titan
Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
PHAT Technical Analysis & Stock Price Forecast - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles - 247wallst.com
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism ) - Seeking Alpha
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade - MarketBeat
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
Barclays Upgrades Phathom Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $18 From $16 - MarketScreener
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook - investing.com
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Weekly Recap: Does Phathom Pharmaceuticals Inc offer margin of safetyTrade Performance Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Whats Phathom Pharmaceuticals Incs historical return2026 Market WrapUp & Weekly High Return Forecasts - baoquankhu1.vn
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Millennium (PHAT) group discloses 4.18M shares (5.3%) in Phathom (PHAT) - Stock Titan
Phathom Pharmaceuticals (PHAT) director gifts 80,000 shares to trust - Stock Titan
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - The Globe and Mail
Phathom Pharmaceuticals (PHAT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
PHAT Should I Buy - Intellectia AI
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom Pharmaceuticals Hits Day Low of $12.32 Amid Price Pressure - Markets Mojo
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):